Understanding and targeting treatment resistance in HER2-positive breast cancer
Project 4
This study is looking at changes in the HER2 gene in breast cancer to find new treatments for patients who don't respond to current therapies, aiming to create more personalized and effective options for those facing tough cases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11171816 on NIH RePORTER |
What this research studies
This research investigates the genetic alterations in breast cancer, particularly focusing on the HER2 gene, which is a key driver in about 20% of breast cancers. The project aims to develop targeted therapies against specific proteins affected by these genetic changes, especially in cases where patients show resistance to existing antibody treatments. By studying a truncated form of HER2 known as p95HER2, the research seeks to uncover mechanisms of treatment resistance and explore new therapeutic strategies. Patients may benefit from advancements in personalized treatment options that are more effective against resistant cancer forms.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with HER2-positive breast cancer, especially those experiencing resistance to existing antibody therapies.
Not a fit: Patients with breast cancer that is not HER2-positive or those who do not have treatment-resistant tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with HER2-positive breast cancer, particularly those who are resistant to current therapies.
How similar studies have performed: Previous research has shown success in targeting HER2-positive breast cancer with antibody therapies, but this specific approach to understanding treatment resistance is novel.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Lucas, Peter C — Mayo Clinic Rochester
- Study coordinator: Lucas, Peter C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.